Glaxo Group Limited

Nerre Therapeutics Limited

Glaxo Wellcome Manufacturing Pte Ltd

Emiliano Castiglioni

Giuseppe Alvaro

Agostino Marasco

Romano Di Fabio

David Amantini

Francesca Pavone

Compounds of formula (I) or pharmaceutically acceptable salts thereof processes for their preparation, compositions containing them, and uses thereof in the treatment of diseases and conditions for which antagonism of NK1 is beneficial.

Spiro (piperidine-4,2'-pyrrolidine)-1-(3,5-trifluoromethylphenyl) methylcarboxamides as NK1 tachikynin receptor antagonists

Compounds of formula (I) or a pharmaceutically acceptable salt thereof. wherein

Spiro (piperidine-4,2'-pyrrolidine)-1-(3,5-trifluoromethyl phenyl) methylcarboxamides as NK1 tachikynin receptor antagonists

Disclosed are N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives having the following formula: wherein m, n, Het, R, Rand Rare as defined herein, and their use as orexin antagonists.

Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine

Growing community of inventors

Verona, Italy

Emiliano Castiglioni